Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-02-03
DOI
10.1038/s41416-021-01260-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Hepatocellular Carcinoma
- (2019) Augusto Villanueva NEW ENGLAND JOURNAL OF MEDICINE
- Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials
- (2019) Robert Montal et al. BRITISH JOURNAL OF CANCER
- Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma
- (2019) Peter R. Galle et al. LIVER INTERNATIONAL
- Early alpha‐foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
- (2019) Yu‐Yun Shao et al. LIVER INTERNATIONAL
- 755PAlpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase III RESORCE trial
- (2019) J Bruix et al. ANNALS OF ONCOLOGY
- Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
- (2018) Ian Chau et al. BRITISH JOURNAL OF CANCER
- Molecular therapies and precision medicine for hepatocellular carcinoma
- (2018) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- 148OAssessment of tumor response, alpha-fetoprotein (AFP) response, and time to progression (TTP) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
- (2018) T Yau et al. ANNALS OF ONCOLOGY
- Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC
- (2017) Andrea Notarpaolo et al. JOURNAL OF HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Changes of alpha-fetoprotein levels could predict recurrent hepatocellular carcinoma survival after trans-arterial chemoembolization
- (2017) Chao He et al. Oncotarget
- VEGF overexpression predicts poor survival in hepatocellular carcinoma
- (2017) Sae Byeol Choi et al. Open Medicine
- Liver transplantation for hepatocellular carcinoma: evaluation of the alpha-fetoprotein model in a multicenter cohort from Latin America
- (2016) Federico Piñero et al. LIVER INTERNATIONAL
- Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan
- (2016) Masatoshi Kudo et al. Liver Cancer
- Genetic Landscape and Biomarkers of Hepatocellular Carcinoma
- (2015) Jessica Zucman-Rossi et al. GASTROENTEROLOGY
- Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation
- (2015) Christian Toso et al. HEPATOLOGY
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- Clinical Implication of Performance Status in Patients with Hepatocellular Carcinoma Complicating with Cirrhosis
- (2015) Hiroki Nishikawa et al. Journal of Cancer
- Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization
- (2013) Yong Kang Lee et al. BMC CANCER
- Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib
- (2013) Takahide Nakazawa et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Targeted inhibition of VEGF receptor 2: an update on ramucirumab
- (2013) Jeffrey Melson Clarke et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Prognostic Significance of Alpha-fetoprotein Status in the Outcome of Hepatocellular Carcinoma after Treatment of Transarterial Chemoembolization
- (2012) Yan Wang et al. ANNALS OF SURGICAL ONCOLOGY
- Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma
- (2012) Young Eun Chon et al. INTERNATIONAL JOURNAL OF CANCER
- Level of α-Fetoprotein Predicts Mortality Among Patients With Hepatitis C–Related Hepatocellular Carcinoma
- (2011) Gia L. Tyson et al. Clinical Gastroenterology and Hepatology
- Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
- (2010) Yu-Yun Shao et al. CANCER
- Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and α-fetoprotein expression status
- (2010) Yun-feng Shan et al. MEDICAL ONCOLOGY
- Significance of Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin in Patients with Hepatocellular Carcinoma Undergoing Hepatectomy
- (2009) Kentaroh Yamamoto et al. ANNALS OF SURGICAL ONCOLOGY
- Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis
- (2009) S J Schoenleber et al. BRITISH JOURNAL OF CANCER
- Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies
- (2009) Puneeta Tandon et al. LIVER INTERNATIONAL
- Serum -Fetoprotein Response as a Surrogate for Clinical Outcome in Patients Receiving Systemic Therapy for Advanced Hepatocellular Carcinoma
- (2009) S. R. Vora et al. ONCOLOGIST
- EpCAM and -Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma
- (2008) T. Yamashita et al. CANCER RESEARCH
- New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy
- (2008) Stephen L. Chan et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now